Viatris (VTRS) Competitors

Pfizer (NYSE:PFE) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Is PFE or VTRS a better dividend stock?

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.8%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 5.2%. Pfizer pays out 124.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Viatris pays out -15.1% of its earnings in the form of a dividend. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Do insiders and institutionals hold more shares of PFE or VTRS?

68.4% of Pfizer shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Comparatively, 0.1% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is PFE or VTRS more profitable?

Pfizer has a net margin of 12.62% compared to Viatris' net margin of -26.45%. Pfizer's return on equity of 20.33% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	12.62%	20.33%	8.53%
Viatris	-26.45%	16.20%	7.01%

Which has better earnings & valuation, PFE or VTRS?

Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$63.63B	2.27	$8.03B	$1.38	18.44
Viatris	$14.74B	0.74	-$634.20M	-$3.17	-2.92

Does the media refer more to PFE or VTRS?

In the previous week, Pfizer had 82 more articles in the media than Viatris. MarketBeat recorded 82 mentions for Pfizer and 0 mentions for Viatris. Pfizer's average media sentiment score of 1.00 beat Viatris' score of 0.00 indicating that Pfizer is being referred to more favorably in the media.

Company	Overall Sentiment
Pfizer	Positive
Viatris	Neutral

Do analysts recommend PFE or VTRS?

Pfizer presently has a consensus price target of $28.55, suggesting a potential upside of 12.20%. Viatris has a consensus price target of $10.40, suggesting a potential upside of 12.43%. Given Viatris' higher probable upside, analysts clearly believe Viatris is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	1 Sell rating(s)	13 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.45
Viatris	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Which has more risk & volatility, PFE or VTRS?

Pfizer has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500.

Summary

Pfizer beats Viatris on 15 of the 20 factors compared between the two stocks.